Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $125.63 +0.88%
EPS Growth %: +32.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +32.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme to Report Third Quarter 2026 Financial and Operating Results
- Schlumberger Ltd. (SLB) Tops Q3 EPS by 2c, Beats on Revenue
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
